Table 3.

Quality evaluation for cost-effectiveness analysis.

Quality Assessment (CiCERO)	Buendía 2021b22	Guevara-Cuellar 201426	Rodríguez‐Martínez 202231	Cintra 201327
Country of conduct	Yes	Yes	Yes	Yes
Population of analysis	Yes	Yes	Yes	Yes
Time horizon	Yes	Yes	Yes	Yes
Perspective	Yes	Yes	Yes	Yes
Discount Rate	Yes	Yes	NA	No
Adjustment of inflation	No	No	NA	No
Interventions compared	Yes	Yes	Yes	Yes
Direct Costs, Capital Costs	Yes	Yes	Yes	Yes
Indirect Medical Costs	No	No	No	No
Indirect Costs	Yes	No	No	No
Valuation of Effectiveness?	Yes	Yes	Yes	Yes
Compliance/adherence with treatment	No	No	No	No
Decision Modelling?	Yes	Yes	Yes	Yes
Cost/Health and/or Economic Outcomes?	Yes	Yes	Yes	No
Uncertainty	Yes	Yes	Yes	Yes*
Conflicts of interest and sources of funding	No	Yes	No	NR
Software	Yes	Yes	Yes	Yes
Were the cost data standardized?	Yes	Yes	Yes	Yes
Was the data synthesised in a de-aggregated manner	Yes	No	Yes	No
Synthesis appropriate to the target audience?	Yes	Yes	Yes	Yes
Separation between “RCT-based economic evaluations” and modeling studies results?	NA	NA	NA	NA
DSA and PSA reported separately?	Yes*	Yes*	Yes	Yes*

NA, not applicable; NR, not reported; DSA, deterministic sensitivity analysis; PSA, probabilistic sensitivity analysis. *: Reporting only deterministic sensitivity analysis.